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PLATELET RESPONSE TO STANDARD ASPIRIN AND CLOPIDOGREL TREATMENT CORRELATES WITH LONG-TERM OUTCOME IN PATIENTS WITH ACUTE ST-ELEVATION MYOCARDIAL INFARCTION
Milicic
Introduction
Platelet activation mediated by multiple signaling pathways and consecutive coronary thrombosis plays a central role in the pathogenesis of acute coronary syndromes, including ST-segment elevation myocardial infarction (STEMI) (1, 2) . Baseline platelet reactivity in these patients is an independent predictor of both successful myocardial reperfusion and the extent of myocardial necrosis after primary angioplasty (3, 4) . Consequently, dual antiaggregation treatment with aspirin and clopidogrel represents the therapeutical mainstay in these patients as it reduces the risk of future cardiac death, myocardial reinfarction and urgent revascularisation.
However, despite antiaggregation, a proportion of patients develops recurrent thrombotic events and the residual rate of re-hospitalization due to worsening of ischemic heart disease or the reoccurrence of MI, stroke and cardiovascular death is around 15% (5) . When measured by ex vivo platelet function assays, the inhibition of platelet aggregation by aspirin and clopidogrel is highly variable and a substantial percentage of patients shows low response to one or both of these drugs (6, 7) . As a result, a considerable concern arises that such a low antiplatelet response might represent one of the risk factors for the development of future adverse cardiovascular events. The impact of antiplatelet variability on the cardiovascular risk was the subject of numerous clinical studies but there is still no definitive answer or guidelines how to manage these patients. The vast majority of studies have enrolled patients with stable coronary disease, non-ST elevation acute coronary syndromes or combined both stable and acute coronary patients, with only one study that exclusively recruited patients with STEMI while solely investigated the impact of clopidogrel response (8) .
This study prospectively evaluated the dynamic of platelet response to both components of standard antiaggregation treatment during early phase in patients with acute STEMI to determine the All patients received 300 mg of chewable aspirin on admission and 100 mg/day thereafter.
Clopidogrel was administered as a loading dose of 600 mg before PCI and followed by 75 mg/day.
Unfractionated heparin was administered during PCI. Eptifibatide infusion was used periproceduraly in 63% of patients during 8 ± 3 hours. 
Platelet function test:
Aggregation testing was done in the whole blood using Multiplate ® ASPI and ADP tests (Dynabyte Medical, Munich, Germany) (9) . Multiplate ® is a computerized «point-of-care» instrument that measures the platelet response to antiplatelet therapy based on the impedance, where a change of the resistance between two electrodes immersed into the testing blood is determined after 6 the addition of specific platelet agonists. Arachidonic acid (AA) with its final concentration of 0.5 mM is used in ASPI test for the measurement of antiplatelet response to aspirin, while ADP at 6.4 mM is used in ADP test for the measurement of clopidogrel effect.
The instrument continuously measures the change in resistance between two silver-coated copper wires that is proportional to the amount of activated platelets adhering to the electrodes and transforms it into "aggregation units" (U). Because two pairs of electrodes are immersed in a single measuring cell, platelet aggregation is always double determined during each test and the final result is calculated from the mean values of the two curves. Pearson's correlation coefficient of the data points detected by each channels is calculated. If the correlation coefficient was lower than 0.98 we have repeated the measurement. In addition, the areas under the aggregation curve detected by each channel are compared and if the difference was higher than 20% vs. the mean value of the two curves, the measurement was also repeated. The Multiplate ® is comparable to the classical «gold standard» i.e.
light transmission aggregometry (LTA) as well as to PFA-100 ® (10, 11) .
Platelet response to aspirin (ASPI test) and clopidogrel (ADP test)
were expressed as an absolute value (U) as well as relative to the baseline aggregation measured at admission (day 1).
Patients were stratified into 4 quartiles according both to the baseline aggregation as well as to the posttreatment reduction of aggregation from the day 1 to day 6.
Blood samples were drawn from antecubital vein and tested within a recommended range of 30 min and 3 h after collection. The compliance to aspirin and clopidogrel was easy to control in the hospital environment. Blood samples for platelet aggregation studies were drawn before loading with dual antiaggregation therapy and primary PCI (day 1), and then daily during the next five days (days 2-6).
All samples after the admission day were taken in the morning after an overnight fast to exclude circadian variation of platelet function. Blood samples were also analyzed for: LDL-cholesterol, triglycerides, blood glucose, glycosylated hemoglobin A (HbA1c), high sensitivity C-reactive protein (hsCRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP) and homocysteine. Creatine phosphokinase (CK) and cardiac troponin T (cTnT) were determined on daily basis, as peaks of total CK and cTnT were recorded. clinical end point, a medical chart review was done to determine whether the event met its definition.
Results
Patient characteristics:
Among 90 patients enrolled, 87 have completed anticipated daily platelet aggregation measurements (from day 1 to day 6) and were successfully followed-up for a one year.
Their median age was 59 years (range 35-88 years) and 60 (69%) were male ( Table 1) . There was no statistically significant difference between patients in 1st quartile and 2nd to 4th quartiles of reduction in AA-induced platelet aggregation in ASPI test with respect to baseline demographic and clinical characteristics, medications assigned to patients as well as to biochemical markers of cardiovascular risk, infarct size or heart failure. However, patients in 1st quartile of reduction in ADP-induced platelet aggregation in ADP test, i.e. those with the lowest response to clopidogrel had significantly more frequent previous myocardial infarction, higher platelet count as well as plasma glucose when compared to patients in 2nd to 4th quartiles ( Table 1) .
Dynamic of platelet response to aspirin and clopidogrel:
Association of baseline platelet reactivity with clinical outcomes:
During the one year followup, 14 patients (16.1%) developed MACCE: 4 patients died (4.6%), 4 patients had recurrent MI (4.6%), 2 patients had stent thrombosis (2.3%), 3 patients had target vessel revascularization (3.4%) and 2 patients developed ischemic stroke (2.3%), one of whom had also recurrent MI. Thus, 14 patients had 15 MACCE in total. There was a gradual increase in incidence of MACCE from the 1st to the 4th quartile of the baseline ADP-induced platelet aggregation. Among 87 patients, 26 patients (29.9%) showed unfavorable response to a single antiplatelet drug, while 52 patients (59.8%) were responders to both aspirin and clopidogrel. Nine patients (10.3%) had suboptimal platelet response to both aspirin and clopidogrel, i.e. belonged to both quartiles of the lowest reduction in AA-and ADP-dependent platelet aggregation. While only 4 patients who were responsive to both components of dual antiaggregation therapy developed some of MACCE (7.7%), this has occurred in 6 patients with suboptimal response to a single antiplatelet drug and in 4 patients who resembled suboptimal platelet inhibition with both aspirin and clopidogrel (44.4%) (P for trend = 0.003) (Figure 4 ).
Discussion
In this study we have evaluated the platelet response to both aspirin and clopidogrel and their relation to clinical outcome exclusively in patients with STEMI. In the landmark study of clopidogrel resistance in STEMI reported by Matetzky et al, patients were treated with 300 mg loading dose while 600 mg used in this study is now considered as a standard loading dose for its more rapid and stronger inhibition of platelet aggregation (12, 13) .
Platelet response to standard dual antiaggregation therapy changes significantly in first days of acute phase STEMI, but than stabilizes after the fourth day of treatment with both aspirin and clopidogrel. This is in concordance with the observation from study of Matetzky et al where no further changes in ADP-dependent aggregation were observed at days 4 through 6 (8).
Baseline ADP-dependent platelet reactivity has been already recognized as a predictor of future adverse clinical outcome (3, 4) . Also, a recent study showed that the initial patency of the infarctrelated artery in patients with acute STEMI during primary PCI was related to platelet response to aspirin (14) . We detected almost geometrical rise in the incidence of recurrent major adverse 
Study limitations
The study population and subsequently the number of adverse clinical events were relatively small. In this study we had to take two blood samples to asses a reduction of platelet reactivity from baseline to posttreatment level as a measure of response to antiplatelet treatment. Such measurements are not always suitable for daily clinical practice. For example, in the settings of 24/7 unavailable aggregometry, a baseline aggregation usually can not be obtained due to need for urgent antiplatelet loading in patients with ACSs. However, in the case of point-of-care method like Multiplate ® this should not be the real problem. Besides, there is increasing number of patients that are already taking chronic antiplatelet therapy and in that case the "true" baseline platelet reactivity can not be assessed.
Conclusions
Even though these data are limited to a relatively small number of cases and require a conformation by larger studies, the observation of significant correlation between antiplatelet status and the future adverse cardiocerebrovascular events (MACCE) suggests that we have an opportunity to stratify the long-term thrombotic risk of patients with STEMI after primary PCI using a simple "point-of-care" aggregometry test like Multiplate ® .
In the future we should examine whether clinical outcome in these patients can be improved by adapting the standard antiplatelet regimen on the basis of the individual risk profile with targeting poor responders to aspirin and/or clopidogrel using higher loading and/or maintenance doses, introduction of GpIIbIIIa inhibitors or novel antiplatelet drugs like prasugrel, ticagrelor or cangrelor. 
